Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.6.4 (
chondroitinase
)
2,039
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have identified a novel ligand for CD44, a cell surface glycoprotein implicated in tumor metastasis and lymphocyte homing. When the mouse T cell line CTLL-2 was transfected with cDNA encoding a hemopoietic form of mouse CD44, CTLL-2 cells exhibited a new self-adhesive phenotype, forming large aggregates. The aggregation was blocked by neutralizing anti CD44 monoclonal antibody but unaffected by hyaluronidase, indicating the involvement of CD44 and its non-hyaluronate ligand in the cell aggregation. The ability to induce CD44-dependent aggregation was found in culture supernatants of CTLL-2 and its CD44 transfectants. The use of CD44-immunoglobulin
chimeric protein
revealed that CTLL-2 and its transfectants synthesized a large-molecular weight protein (gp600) which bound specifically to CD44. The gp600 was readily labeled with radioactive sulfate, and treatment of gp600 with
chondroitinase
ABC or ACII generated a lower molecular weight species (18-22 kDa), suggesting that gp600 consists of a small core protein with chondroitin sulfate glycosaminoglycan side chains. However, binding of CD44 to glycosaminoglycans such as chondroitin 4-sulfate, chondroitin 6-sulfate, and dermatan sulfate was undetectable, suggesting either that a novel chondroitin-type glycosaminoglycan is recognized by CD44 or that a particular configuration of the glycosaminoglycan is required for recognition by CD44.
...
PMID:A sulfated proteoglycan as a novel ligand for CD44. 2292 40
In situ binding of (chimeric) proteins to tissue sections is a widely used method to identify ligands and their localization. Many different protocols for the fixation of frozen tissue sections are used for in situ binding studies. We report the effects of different fixation protocols on the binding pattern observed using in situ binding of an L-selectin-IgM
chimeric protein
to both rat lymph node and kidney tissue sections. L-selectin is a C-type lectin, expressed on leukocytes and is involved in both lymphocyte homing and migration upon inflammation. We show that different in situ binding patterns in rat kidney are observed using different fixation protocols, including glutaraldehyde, methanol, formaldehyde and acetone fixation. The observed staining is specific, as it can be blocked in the presence of EGTA, an L-selectin blocking antibody or by ligand competition. Enzymatic pre-treatment of the tissue sections using sialidase, heparitinase I or
chondroitinase
ABC has differential effects on in situ binding depending on tissue type and fixation protocol. These data indicate that special attention should be paid in choosing a fixation protocol for in situ binding studies, especially when using lectins. This could prevent biologically relevant ligands remaining undetected or wrong conclusions being drawn based on the localization of observed binding.
...
PMID:Effect of fixation protocols on in situ detection of L-selectin ligands. 1584 5